Publication date: Jul 16, 2019
Growth of the Huntington’s disease treatment market is driven by rising prevalence of disease and increasing R&D programs by institutes and universities.
Organization such as CHID Foundation, Hereditary Disease Foundation, Huntington’s Disease Society of America, and International Huntington Association aid in creating awareness among patients and their family, which is also expected to support growth of the Huntington’s disease treatment market.
However, social stigma related to Huntington’s disease, stringent regulations related to drug approvals, and limited approved drug are factors expected to negatively affect growth of the Huntington’s disease treatment market.
Huntington’s disease treatment market is dominated by off-labeled drugs, which creates opportunity for key players, to develop new drugs.
Therefore, development of various new therapies for treatment of Huntington’s disease is expected to aid in growth of the market over the forecast period.
Valeant Pharmaceuticals International Inc. , Alnylam Pharmaceuticals Inc. , Ceregene Inc. , Lundbeck, Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd. , Cortex Pharmaceuticals Inc. , Vertex Pharmaceuticals Incorporated, Auspex Pharmaceuticals, SOM Biotech, GlaxoSmithKline, Siena Biotech, Raptor Pharmaceutical, Pfizer limited, Palobiofarma S. L, Omeros and Ipsen are the major players operating in Huntington’s disease treatment market.
- Huntington’s Disease Therapy Uses the Power of Repression
- Why the absence of hope may be hurting Huntington’s disease research